Alarmins firing arthritis: Helpful diagnostic tools and promising therapeutic targets

Joint Bone Spine

Volumn 84, Issue 4, 2017, Pages 401-410

  Lavric, Miha ^a   Miranda García, María Auxiliadora ^a   Holzinger, Dirk ^a   Foell, Dirk ^a   Wittkowski, Helmut ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Alarmins; Arthritis; Biomarkers; DAMPs; Pathology

Indexed keywords

ALARMIN; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 33; PROTEIN S 100; URATE; URIC ACID; BIOLOGICAL MARKER;

ARTHRITIS; CRYSTAL; DISEASE SEVERITY; EXPERIMENTAL MODEL; GOUT; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; PHAGOCYTE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SPONDYLARTHRITIS; ANIMAL; BLOOD; DISEASE MODEL; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALARMINS; ANIMALS; ARTHRITIS; BIOMARKERS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION;

EID: 85011074181     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2016.06.010     Document Type: Short Survey

References (65)

1. Foell, D., Wittkowski, H., Roth, J., Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 3 (2007), 382–390.
2. Andersson, U., Harris, H.E., The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 1799 (2010), 141–148.
3. Kessel, C., Holzinger, D., Foell, D., Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol 147 (2013), 229–241.
4. Jia, H., Halilou, A.I., Hu, L., et al. Heat shock protein 10 (Hsp10) in immune-related diseases: one coin, two sides. Int J Biochem Mol Biol 2 (2011), 47–57.
5. Srivastava, P., Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2 (2002), 185–194.
6. Tukaj, S., Kotlarz, A., Jozwik, A., et al. Hsp40 proteins modulate humoral and cellular immune response in rheumatoid arthritis patients. Cell Stress Chaperones 15 (2010), 555–566.
7. Vercoulen, Y., van Teijlingen, N.H., de Kleer, I.M., et al. Heat shock protein 60 reactive T cells in juvenile idiopathic arthritis: what is new?. Arthritis Res Ther, 11, 2009, 231.
8. Martin, N.T., Martin, M.U., Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol 17 (2016), 122–131.
9. Liew, F.Y., IL-33: a Janus cytokine. Ann Rheum Dis 71:Suppl 2 (2012), i101–i104.
10. Busso, N., So, A., Mechanisms of inflammation in gout. Arthritis Res Ther, 12, 2010, 206.
11. So, A., Busso, N., The concept of the inflammasome and its rheumatologic implications. Joint Bone Spine 81 (2014), 398–402.
12. Przybysz, M., Borysewicz, K., Katnik-Prastowska, I., Fibronectin molecular status determination useful to differentiate between rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatol Int 33 (2013), 37–43.
13. Varga, G., Gattorno, M., Foell, D., et al. Redox distress and genetic defects conspire in systemic autoinflammatory diseases. Nat Rev Rheumatol 11 (2015), 670–680.
14. Killeen, M.E., Ferris, L., Kupetsky, E.A., et al. Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J Immunol 190 (2013), 4324–4336.
15. Leadbetter, E.A., Rifkin, I.R., Hohlbaum, A.M., et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 (2002), 603–607.
16. Liang, J., Jiang, D., Noble, P.W., Hyaluronan as a therapeutic target in human diseases. Adv Drug Deliv Rev 97 (2016), 186–203.
17. Zhang, Q., Raoof, M., Chen, Y., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464 (2010), 104–107.
18. Holzinger, D., Nippe, N., Vogl, T., et al. Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout. Arthritis Rheumatol 66 (2014), 1327–1339.
19. Mylona, E.E., Mouktaroudi, M., Crisan, T.O., et al. Enhanced interleukin-1beta production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Res Ther, 14, 2012, R158.
20. Crisan, T.O., Cleophas, M.C., Oosting, M., et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis 75 (2016), 755–762.
21. McInnes, I.B., Buckley, C.D., Isaacs, J.D., Cytokines in rheumatoid arthritis – shaping the immunological landscape. Nat Rev Rheumatol 12 (2016), 63–68.
22. van Eden, W., van der Zee, R., Prakken, B., Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 5 (2005), 318–330.
23. de Kleer, I.M., Wedderburn, L.R., Taams, L.S., et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 172 (2004), 6435–6443.
24. Kamphuis, S., Kuis, W., de Jager, W., et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 366 (2005), 50–56.
25. Geczy, C.L., Chung, Y.M., Hiroshima, Y., Calgranulins may contribute vascular protection in atherogenesis. Circ J 78 (2014), 271–280.
26. Palmblad, K., Schierbeck, H., Sundberg, E., et al. High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Mol Med 20 (2014), 538–547.
27. Hofmann, M.A., Drury, S., Hudson, B.I., et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3 (2002), 123–135.
28. Li, C., Mu, R., Guo, J., et al. Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res Ther, 16, 2014, R105.
29. Vinasco, J., Beraun, Y., Nieto, A., et al. Heat shock protein 70 gene polymorphisms in rheumatoid arthritis. Tissue Antigens 50 (1997), 71–73.
30. Rothmund, F., Gerss, J., Ruperto, N., et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res 66 (2014), 949–955.
31. Holzinger, D., Frosch, M., Kastrup, A., et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71 (2012), 974–980.
32. Anink, J., Van Suijlekom-Smit, L.W., Otten, M.H., et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther, 17, 2015, 200.
33. Foell, D., Wulffraat, N., Wedderburn, L.R., et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303 (2010), 1266–1273.
34. Choi, I.Y., Gerlag, D.M., Herenius, M.J., et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis 74 (2015), 499–505.
35. Hammer, H.B., Odegard, S., Syversen, S.W., et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 69 (2010), 150–154.
36. Wittkowski, H., Frosch, M., Wulffraat, N., et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58 (2008), 3924–3931.
37. Gerss, J., Roth, J., Holzinger, D., et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 71 (2012), 1991–1997.
38. Foell, D., Kane, D., Bresnihan, B., et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 42 (2003), 1383–1389.
39. Chen, Y., Sun, W., Li, S., et al. Preliminary study of high mobility group box chromosomal protein 1(HMGB1) in ankylosing spondylitis patients. Clin Exp Rheumatol 33 (2015), 187–194.
40. Matsuyama, Y., Okazaki, H., Tamemoto, H., et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 37 (2010), 18–25.
41. Lee, E.J., So, M.W., Hong, S., et al. Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis. Cytokine 77 (2016), 35–43.
42. Li, X.L., Lin, T.T., Qi, C.Y., et al. Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor. J Investig Med 61 (2013), 848–851.
43. Foell, D., Roth, J., Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 50 (2004), 3762–3771.
44. Gondokaryono, S.P., Ushio, H., Niyonsaba, F., et al. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol 82 (2007), 657–665.
45. Schierbeck, H., Pullerits, R., Pruunsild, C., et al. HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J Rheumatol 40 (2013), 1604–1613.
46. Ishikawa, S., Shimizu, M., Ueno, K., et al. Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis. Cytokine 62 (2013), 272–277.
47. Talabot-Ayer, D., McKee, T., Gindre, P., et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 79 (2012), 32–37.
48. Cheng, Y., Chen, Y., Sun, X., et al. Identification of potential serum biomarkers for rheumatoid arthritis by high-resolution quantitative proteomic analysis. Inflammation 37 (2014), 1459–1467.
49. Ostberg, T., Kawane, K., Nagata, S., et al. Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum 62 (2010), 2963–2972.
50. Musumeci, D., Roviello, G.N., Montesarchio, D., An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther 141 (2014), 347–357.
51. Helmersson, S., Sundstedt, A., Deronic, A., et al. Amelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: reduced priming of proinflammatory effector CD4(+) T cells. Am J Pathol 182 (2013), 1671–1680.
52. Lim, S.Y., Raftery, M., Cai, H., et al. S-nitrosylated S100A8: novel anti-inflammatory properties. J Immunol 181 (2008), 5627–5636.
53. Monnet, E., Shang, L., Lapeyre, G., et al. AB0451 NI-0101, a monoclonal antibody targeting toll like receptor 4 (TLR4) being developed for rheumatoid arthritis (RA) treatment with a potential for personalized medicine. Ann Rheum Dis, 74, 2015, 1046.
54. Koffeman, E.C., Genovese, M., Amox, D., et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 60 (2009), 3207–3216.
55. Leavenworth, J.W., Tang, X., Kim, H.J., et al. Amelioration of arthritis through mobilization of peptide-specific CD8+ regulatory T cells. J Clin Invest 123 (2013), 1382–1389.
56. Wendling, U., Paul, L., van der Zee, R., et al. A conserved mycobacterial heat shock protein (hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue. J Immunol 164 (2000), 2711–2717.
57. Vande Walle, L., Van Opdenbosch, N., Jacques, P., et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512 (2014), 69–73.
58. Cavagna, L., Taylor, W.J., The emerging role of biotechnological drugs in the treatment of gout. Biomed Res Int, 2014, 2014, 264859.
59. Palmer, G., Talabot-Ayer, D., Lamacchia, C., et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 60 (2009), 738–749.
60. Keystone, E.C., Wang, M.M., Layton, M., et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 71 (2012), 1630–1635.
61. Kimball, A.B., Krueger, J., Sullivan, T., et al. IMO-3100, an antagonist of Toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a phase 2a trial. J Invest Dermatol, 133, 2013, S26.
62. Baroja-Mazo, A., Pelegrin, P., Modulating P2X7 receptor signaling during rheumatoid arthritis: new therapeutic approaches for bisphosphonates. J Osteoporos, 2012, 2012, 408242.
63. Coll, R.C., Robertson, A., Butler, M., et al. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE, 6, 2011, e29539.
64. McGarry, T., Connolly, M., Coll, R.C., et al. Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis. Arthritis Rheumatol, 66, 2014, S461.
65. Thwaites, R., Chamberlain, G., Sacre, S., Emerging role of endosomal toll-like receptors in rheumatoid arthritis. Front Immunol, 5, 2014, 1.